Dermatology

Tremfya found to achieve significantly clearer skin in moderate to severe plaque psoriasis.

Top articles of the week from Specialty Pharmacy Times.

Study will examine the safety and efficacy of tralokinumab monotherapy in treating atopic dermatitis.

Tralokinumab is a novel human monoclonal antibody that targets a cytokine key in the development of atopic dermatitis.

Erelzi (etanercept) indicated to treat multiple inflammatory conditions.

There are nearly 1000 products in development for dermatological conditions.

Psoriasis drugs Cosentyx and Taltz demonstrated significantly more remissions in patients with psoriasis.

Psoriasis drugs achieve positive effects in remission and health-related quality of life.

Agents fight cancer by temporarily loosening DNA, increasing the expression of tumor suppressors, and making the tumor more vulnerable.

Low-cost generic topical steroids could save Medicare $944.8 million.

Psoriasis is an itchy, uncomfortable, hyperproliferative dermatologic condition that tends to affect patients’ elbows, knees, scalp, umbilicus, lumbar regions, fingernails, toenails, and areas with skinfolds.

Adalimumab (Humira) demonstrated skin clearance among patients with fingernail psoriasis.

Women observed to have significantly lower Psoriasis Area Severity Index scores than men.

Injection helps clear skin and manage itch severity caused by the disease.

The FDA has approved Dupixent (dupilumab) injection, from Sanofi and Regeneron Pharmaceuticals, for the treatment of adults with inadequately controlled moderate-to-severe atopic dermatitis (AD).

A majority of patients experienced the same level of skin clearing as initial treatment with Cosentyx.

Atopic dermatitis drug improves overall disease severity in phase 3 clinical trial.

GP2017 observed to reduce symptoms among patients with moderate-to-severe chronic plaque psoriasis.

Diseases such as multiple sclerosis, lupus, and psoriasis showed a statistically significant association with dementia.

Top news of the day from across the health care landscape.

Extensive psoriasis lesions remained in 18% of patients undergoing treatment.

Brodalumab (Siliq) approved to treat adults with moderate-to-severe plaque psoriasis.

Siliq prevents an inflammatory response that plays a role in the development of plaque psoriasis.

The FDA has approved Valeant Pharmaceuticals’ Siliq (brodalumab) injection for subcutaneous use in adults with psoriasis.

Abbreviated new drug applications were accepted for 3 topical generic products on December 30, 2016.